Statements (53)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:bfsLayer |
4
|
gptkbp:bfsParent |
gptkb:Nexium
|
gptkbp:activities |
gptkb:railway_station
|
gptkbp:brand |
gptkb:Prevacid
Zoton |
gptkbp:category |
B
|
gptkbp:clinical_trial |
Phase IV
Phase III |
gptkbp:composed_of |
reduction reaction
cyclization reaction oxidation reaction N-alkylation N-oxidation deprotection reaction hydrolysis reaction ring closure reaction sulfonamide reaction |
gptkbp:contraindication |
severe liver disease
hypersensitivity to lansoprazole |
gptkbp:excretion |
urine
|
gptkbp:form |
gptkb:beer
gptkb:tablet suspension |
gptkbp:healthcare |
gptkb:1995
|
https://www.w3.org/2000/01/rdf-schema#label |
lansoprazole
|
gptkbp:ingredients |
C16 H19 N3 O2 S
|
gptkbp:interacts_with |
gptkb:methotrexate
gptkb:clopidogrel gptkb:digoxin gptkb:warfarin |
gptkbp:is_atype_of |
A02 B C03
|
gptkbp:is_available_on |
over-the-counter
prescription |
gptkbp:is_used_for |
treating gastroesophageal reflux disease (GERD)
treating peptic ulcers treating Zollinger-Ellison syndrome |
gptkbp:lifespan |
gptkb:healthcare_organization
1.5 hours stomach cancer bone fractures low magnesium levels |
gptkbp:manager |
oral
|
gptkbp:metabolism |
liver
|
gptkbp:side_effect |
headache
nausea abdominal pain diarrhea constipation |
gptkbp:treatment |
gptkb:GERD
peptic ulcers erosive esophagitis |
gptkbp:type_of |
103577-45-3
|